Showing 4741-4750 of 7765 results for "".
- Take That, Kim and Kylie : Most Millennials Don't Want Your Advice on Cosmetic Surgeryhttps://practicaldermatology.com/news/take-that-kim-and-kylie/2457812/When it comes to deciding on nips and tucks, millennials are not inclined to trust social media or celebs, a new
- FDA Approves Sonoma Pharmaceuticals' Antimicrobial Post-Therapy Gelhttps://practicaldermatology.com/news/fda-approves-sonoma-pharmaceuticals-antimicrobial-post-therapy-gel/2457813/Sonoma Pharmaceuticals, Inc. has received a new 510(k) clearance from the FDA for an antimicrobial post-therapy gel. Under the supervision of a healthcare professional, the new product is intended for the management of post-non-ablative laser therapy procedures and post-microdermabrasion therapy
- Coming Soon to a City Near You: Sciton Inc.'s Bright Lights Big City BBL 2018 Tourhttps://practicaldermatology.com/news/coming-soon-to-a-city-near-you-sciton-incs-bright-lights-big-city-bbl-2018-tour/2457815/Sciton. Inc.’s Bright Lights Big City BroadBand Light (BBL) 2018 Tour is now in its third year. The 2018 Tour, featuring San Francisco dermatologist Patrick Bitter Jr., MD, kicks off in early June in For
- With New Team, Revance Readies for Launch of their Botox Competitorhttps://practicaldermatology.com/news/with-new-team-revance-readies-for-launch-of-their-botox-competitor/2457819/With the advent of four new positions, Revance Therapeutics is expanding their commercialization team in anticipation of the product launch of for DaxibotulinumtoxinA for Injection (RT002) in the treatment of glabellar lines.
- DefenAge® Skincare Trio Performs Well in New Studyhttps://practicaldermatology.com/news/defenage-skincare-trio-performs-well-in-new-study/2457818/Progenitor Biologics’ DefenAge® Skincare, a-three-step system “globally improves the visual appearance of aging skin without irritation, dryness, or inflammation,” according to new research in the
- Hydrogen Peroxide 40% Less Cytotoxic Than Cryotherapy: Studyhttps://practicaldermatology.com/news/hydrogen-peroxide-40-less-cytotoxic-than-cryotherapy-study/2457822/Hydrogen peroxide topical solution 40% (Eskata, Aclaris) is less cytotoxic to living cells and less damaging to melanocytes than cryosurgery, according to a new study led by Adam Friedman, MD, associate professor of dermatology at the GW School of Medicine and Health Sciences. <
- Researchers Assess Tools to Measure QoL Impact of Skin Conditionshttps://practicaldermatology.com/news/researchers-assess-tools-to-measure-qol-impact-of-skin-conditions/2457827/Boston University School of Medicine researchers have set out to find the best tool to measure the impact of skin coniditons on patients' quality of life. Several dermatology and disease-specific tools have been developed to measure the impact of skin disease including the widel
- Proscia Inks Agreement to Bring Deep-Learning Technology to Dermatopathologyhttps://practicaldermatology.com/news/proscia-inks-agreement-to-bring-deep-learning-technology-to-dermatopathology/2457832/Proscia Inc., creators of AI-powered digital pathology software, signed a first-of-its-kind agreement with one of the largest dermatopathology labs in the country. This agreement provides Proscia with exclusive access to pathology slides and expert pathologist ground-truth data for an arr
- Hair Restoration Technique Updates Name to Reflect Surgical Nature of Procedurehttps://practicaldermatology.com/news/hair-restoration-technique-updates-name-to-reflect-surgical-nature-of-procedure/2457836/The International Society of Hair Restoration Surgery (ISHRS) has updated the terminology of the hair transplantation method known as FUE from Follicular Unit Extraction to Follicular Unit Excision. The ISHRS explains that this cha
- First Patient Dosed in Proof-of-Concept Trial of Topical by Design JAK Inhibitor SNA-125 for Atopic Dermatitishttps://practicaldermatology.com/news/first-patient-dosed-in-proof-of-concept-trial-of-topical-by-design-jak-inhibitor-sna-125-for-atopic-dermatitis/2457839/The first patient has been dosed in Sienna Biopharmaceuticals, Inc.'s Phase 1/2 proof-of-concept clinical trial of topical product candidate SNA-125 in the treatment of atopic dermatitis and the associated pruritus. SNA-125 is designed to inhibit Janus kinase 3, or JAK3, and tropomyosin recep